Mumbai, October 23 (Udaipur Kiran) — Shares of Glenmark Pharmaceuticals gained nearly 1% in Thursday’s trading session after the company announced that its US-based subsidiary is preparing to launch Ropivacaine Hydrochloride Injection USP in multiple dosage strengths.
The stock was trading at ₹1,873.20, up by ₹17.50 or 0.94%, from its previous close of ₹1,855.70 on the BSE. It opened at ₹1,870.00 and touched an intraday high of ₹1,878.00 and a low of ₹1,853.85. Around 4,298 shares were traded on the counter.
Glenmark’s market capitalisation currently stands at ₹52,722.17 crore. The stock has a 52-week high of ₹2,286.15 (July 11, 2025) and a 52-week low of ₹1,274.70 (February 28, 2025). Over the last week, it traded between ₹1,977.25 and ₹1,860.05.
Promoters hold 46.65%, while institutional investors own 39.38% and non-institutional investors 13.97% of the company’s shares.
New US Launch Details
Glenmark Pharmaceuticals’ US arm — Glenmark Pharmaceuticals Inc. — will launch Ropivacaine Hydrochloride Injection USP in three variants:
-
40 mg/20 mL (2 mg/mL)
-
150 mg/30 mL (5 mg/mL)
-
200 mg/20 mL (10 mg/mL)
These are single-dose vials that are bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection (Fresenius Kabi USA, LLC; NDA – 020533). Glenmark’s US unit is expected to begin distribution in November 2025.
According to IQVIA sales data for the 12-month period ending August 2025, the Naropin Injection market achieved annual sales of approximately $20.9 million, indicating a strong opportunity for Glenmark to capture market share.
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals is a global research-driven pharmaceutical company with diversified operations across Generics, Specialty, and OTC segments, and a strong presence in over 50 countries. The company continues to expand its US portfolio with new product launches in niche and specialty therapeutic areas.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.